Lasers useful for promoting hair growth
The idea of using light to stimulate hair growth was first published in the 1960s and involved mice studies (Mester E, Szende B, et al. Kiserl Orvostud. 1967;19:628-631). Despite this history, the mechanism of action of how lasers may function to prevent, stop or even promote growth in AGA is still unknown.
LLLT and hair growth
There is clear evidence that low-level lasers alter cell function in some manner, and low-level laser therapy (LLLT) for wound healing, pain, anti-aging and inflammation is a popular — yet relatively unproven — modality. In vitro studies with different wavelengths have shown modulation of cell activity, including increased mitochondrial activity as well as increased production of ATP.
This "stimulatory effect" of light therapy is what has driven scientists and physicians to explore low-level laser photobiomodulation for hair growth. Clinically, LLLT does seem to provide some effect, although in some treatments it is difficult to measure. When it comes to AGA, most of the focus has been on red and near-infrared light devices (600 nm to 950 nm).
Ironically, many of the reports on hair growth and lasers actually originated from laser hair removal literature. Stimulation of hair growth is an adverse event associated with hair removal with intense pulsed light (IPL), diode and alexandrite lasers. If we could predictably control this "adverse event" and elicit it in patients who actually desire more hair, a new therapeutic option could emerge.
Several authors have tried to find the common variables in those patients experiencing paradoxical hair growth during laser hair removal. The percentage of patients treated for hair removal who experience hair growth is small (less than 1 percent, from all published reports). Patients with darker skin types (IV) treated with the alexandrite laser for hair removal were more prone to hair growth than those with lighter skin types (Alajlan A, et al. J Am Acad Dermatol. 2005;53(1):85-88).
Apart from one report of several women with polycystic ovarian syndrome, there are no set risk factors for hair growth in this subset of laser hair removal patients. (Moreno-Arias G, et al. Dermatol Surg. 2002;28(11):1013-1016). In general, when treating patients for hair removal with the alexandrite, those with darker skin types will receive lower-fluence treatments to avoid dyspigmentation. It may be this relatively low-fluence therapy that, in fact, puts someone at risk for hair growth, though this has yet to be substantiated with clear data.
Hair growth studies
Laser-induced hair growth in mice has been replicated using several different devices, including a helium-neon (He-Ne) laser (Shukla S, et al. Skin Pharmacol Physiol. 2010;23(2):79-85). In this study, mice treated with the He-Ne laser had a much higher percentage of hairs in anagen phase than those not treated.
There is one published double-blind, sham device-controlled, multicentered study on hair growth (Leavitt M, et al. Clin Drug Invest. 2009;29(5):283-295). A total of 123 patients with AGA were enrolled in this well-designed, company-sponsored trial. Hair counts were completed, as were photographic assessments and patient self-assessment scores. The treatment group used a low-level laser comb (655 nm, HairMax LaserComb, Lexington International) 15 minutes a day, three days a week, for a total of 26 weeks. Hair counts at the end of six months showed a statistically significant (p<.0001) difference in hair density counts between the laser group and the sham group (+19.8 hairs/cm2 vs. -7.6 hairs/cm2 ). There was also a statistically significant difference in the subjects' self assessments. However, blinded investigator clinical assessments did not demonstrate a statistically significant difference between the treatment and sham groups.
While LLLT with red light does stimulate terminal growth on hair count analysis, the clinical improvement is more difficult to judge. The study did not evaluate for any textural changes in hair. Textural changes may make hair appear clinically fuller, and patients may be happy with "thicker" hair that doesn't necessarily exhibit a higher hair count. It may be that longer treatment sessions or duration of the treatment is needed. It may also be more helpful clinically when used in combination with other therapies, such as hair transplant, finasteride or minoxidil.
Currently, there are several devices available on the market that use lasers for hair growth. All utilize wavelengths of 630 nm to 670 nm and are categorized as nonsignificant risk (NSR) devices. The most popular hair-growth laser devices for home use are the Hair Max LaserComb (FDA 510(k)); the Laser Hair Brush (Sunetics); the X5 Hair Laser (Spencer Forrest); and the Aculas HB-850 (Konftec).
These devices contain different numbers and arrays of laser diodes ranging in power from 2 mW to 20 mW per diode and a total power of 20 mW to 100 mW. These units are hand-held, and the recommended treatment protocols are 10 to 15 minutes, two to three days per week. The patient must sequentially move the device during the treatment period to ensure coverage of the entire affected area.
In-office LLLT systems resemble salon dryer "hoods" and are available with higher total-dose delivery (up to 2,000 mW) than the at-home devices. One example is the Sunetics Model "G" Laser, which has an open hood composed of four panels containing a total of 107 5-mW laser diodes to treat the entire top-scalp area. These in-office treatments also come with a bigger price tag (around $3,500 to $5,000 per year for the patient).
In February, an in-office device known as the MEP-90 hair growth stimulation system (Midwest RF) received FDA 510(k) clearance for the treatment of AGA in female patients. It is currently the only device specifically studied and approved for women. At-home versions of the in-office devices are also available on the Internet, though it is difficult to ascertain the actual parameters of the device.
Recently, a home-use device with greater laser power than most in-office systems was developed under the name LaserCap (Transdermal Cap). It contains 224 5-mW laser diodes in a mesh network that covers the entire top of the scalp and fits under a hat or cap. It has a rechargeable battery so that treatment can be administered while "on the go" in a convenient, discreet fashion. The LaserCap is available to patients through physicians at a rental cost and is currently undergoing further clinical evaluation.
Optimum treatment frequency and duration have not yet been determined for hair-growth laser therapy, and it is theoretically possible that large overdoses could reverse the therapeutic effects. In other words, more power with LLLT does not necessarily translate into better results. Long-term follow-up of patients receiving LLLT for AGA is needed to determine if therapeutic benefits can be maintained with prolonged therapy.
Laser and light devices have been used in other types of hair loss, including alopecia areata (AA). Lasers for use in AA primarily function via immunomodulation, targeting the primary pathology in this condition. The eximer laser (308 nm) has shown success in several trials for this disease via the mechanism of ultraviolet immunosuppression (Al-Mutairi N. Dermatol Surg. 2007;33(12):1483-1487). While effective in AA, the eximer laser is not likely to be useful for nonimmune types of hair loss, such as AGA.
In summary, LLLT is a safe, tolerable and easy-to-use treatment option for patients with AGA. Hair counts have been shown to increase in the only double-blinded study published. Proper parameters and treatment regimens must be better elucidated in order to make this treatment more universally accepted.
At this point, LLLT (red, 630 nm to 670 nm) for AGA seems to show some effects in some patients, yet future studies are needed to optimize results by better defining treatment power, dosing and frequency. With so few reliable noninvasive therapeutic choices for AGA, laser therapy is a welcome addition.
Joely Kaufman, M.D., is assistant professor of clinical dermatology at the University of Miami Miller School of Medicine and director of lasers for the University of Miami Cosmetic Group.
Bernard Nusbaum, M.D., is a board-certified dermatologist specializing in hair loss and hair restoration. He is past president of the American Board of Hair Restoration Surgery and co-editor of Hair Transplant Forum International.
MORE ARTICLES IN THIS ISSUE
Rosacea is a fairly common inflammatory skin condition that can prove challenging to treat. Current therapeutic strategies empirically target the signs and symptoms of the disease, because the details of its pathophysiology have not yet been completely understood.
Although recent vitamin D research suggests that higher vitamin D levels might improve some health outcomes, these data are largely inconclusive and sometimes contradictory, dermatologists say. Moreover, they continue to recommend oral supplementation rather than intentional sun exposure for those interested in elevating their levels.
2010 marks the 25th anniversary of three pioneering skin cancer prevention programs launched by the American Academy of Dermatology (AAD).
The biopsy is a major revenue source for dermatology practices, emphasizing the need for correct biopsy billing practices. Dermatology practices tend to make mistakes in two key areas: basing their billing on intent, and in misrepresenting services.
The ad beckons all to use skincare products developed specifically to work with your genes. Just take the wooden stick out of the pouch, rub it vigorously inside your mouth, rinse the stick in the vial of magic liquid, seal and mail to the company. In about three weeks, you will receive in the mail a box of skincare products developed specifically for your unique genetic makeup.
As reimbursement declines and overhead rises, dermatologists can't afford anything short of a perfect billing and collections process. Successful billing outcomes depend on many factors, and entrusting the entire process to someone else without appropriate oversight simply isn't smart business.
Dermatologist and Mohs surgeon Ellen Marmur, M.D., knows skin cancer. She performs about 1,000 skin cancer surgeries a year as chief of the division of dermatology and cosmetic surgery, Mount Sinai Medical Center, New York. But when a suspicious lesion showed up on her nose, she did not want to think the worst.
Organized medicine, including groups representing dermatologists, has long fought for medical liability reforms that would limit jury-granted noneconomic awards for pain and suffering and include provisions to keep frivolous (but potentially costly) cases out of court. Their pitch: Effective reform would reduce medical malpractice costs, including insurance, and make it possible for many physicians who can't afford skyrocketing premiums to continue their practices.
A recent study documenting addictive behavior in indoor tanners suggests physicians must change their tactics in addressing such individuals, say study authors and a dermatologist.
Where do dermatologists find themselves falling in their assessment of the healthcare reform legislation in the U.S.? On Call found dermatologists who place themselves in each of the camps, as well as a group that wishes someone could explain what the legislation actually does.
Radiofrequency (RF) technology has come a long way since its inception in aesthetic medicine. The EndyMed Pro (EndyMed Medical) is a new RF device using 3DEEP technology that appears to set itself apart in the way it delivers RF energy. The new technology was presented at the 68th annual meeting of the American Academy of Dermatology.
Clinicians need to keep in mind possible differential diagnoses that mimic rosacea when they see patients who exhibit symptoms that appear to suggest the disease, according to the director of the Bikowski Skin Care Center.
A German team is exploiting the genetic connection between actinic keratosis (AK) and the human papillomavirus (HPV) by developing an HPV-specific vaccine for Aks and invasive squamous cell carcinoma (SCC), according to a team member who spoke at MauiDerm 2010: Advances in Cosmetic and Medical Dermatology.
Dr. Cellulite prides himself on the fact that he is the only dermatologist performing mesotherapy cellulite treatments in his area. He uses a technique called "lipodissolve." He, like most healthcare practitioners doing this technique, uses a substance called deoxycholate. He advertises that this technique is both safer and more effective than liposuction.
A device for performing in-office electron radiation therapy (DermaBeam with Mobetron, IntraOp Medical) allows dermatologists to offer an entire gamut of skin cancer treatment modalities, and better meet the varying needs of individual patients.
Recent trial data show that a new lower-dose regimen of imiquimod proves effective in the treatment of actinic keratosis (AK) and allows patients to treat much larger surface areas of clinical as well as subclinical lesions. Study results were recently presented at the 68th Annual Meeting of the American Academy of Dermatology.
Keeping good closures from going bad requires not only thorough patient education and surgical planning by the physician, but also patient adherence to pre- and post-surgical instructions, according to an expert who spoke at the 68th annual meeting of the American Academy of Dermatology.
For years, people have been trying to make expensive razor blades last longer. The currently marketed razor blade cartridges are designed to last five to seven uses. However, blade life is reduced if the razor is dropped and the blade dented. Dropping the razor immediately dulls the blade, and it should be discarded.
A new study on pollution from active pharmaceutical ingredients (APIs) has uncovered a previously unrecognized means by which drug residues are released into the environment. The study's authors say the findings could lead to new ways to control environmental pollution from APIs.
Niacinamide can be an effective treatment for the inflammation related to rosacea, according to Helen M. Torok, M.D. The etiology of rosacea is unknown, although research has shown that symptoms are exacerbated by factors that trigger innate responses, such as the release of cathelicidin antimicrobial peptides.